Anna Maria Camarda, Giulia Fontana, Barbara Vischioni, Amelia Barcellini, Maria Bonora, Jessica Franzetti, Nadia Facchinetti, Federica Serra, Carmine Tinelli, Rossana Ingargiola, Sara Ronchi, Viviana Vitolo, Pierluigi Bonomo, Sara Colombo, Daniela Alterio, Nicola Alessandro Iacovelli, Marzia Franceschini, Giovanni Ivaldi, Marco Trovò, Elisa D'Angelo, Ester Orlandi
{"title":"组合:碳离子与光子或质子促进唾液腺和鼻窦癌。","authors":"Anna Maria Camarda, Giulia Fontana, Barbara Vischioni, Amelia Barcellini, Maria Bonora, Jessica Franzetti, Nadia Facchinetti, Federica Serra, Carmine Tinelli, Rossana Ingargiola, Sara Ronchi, Viviana Vitolo, Pierluigi Bonomo, Sara Colombo, Daniela Alterio, Nicola Alessandro Iacovelli, Marzia Franceschini, Giovanni Ivaldi, Marco Trovò, Elisa D'Angelo, Ester Orlandi","doi":"10.1111/odi.70086","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the outcomes of combining carbon ion radiotherapy boost (CIRTb) with photons (Ph) or protons (PT) for locally advanced salivary gland and sinonasal cancers (SGCs and SNCs).</p><p><strong>Materials and methods: </strong>Sixty-nine patients with SGCs and SNCs received CIRTb to high-risk CTV and Ph or PT to low-risk CTV (LR-CTV) from October 2014 to September 2022. Two-year local relapse-free survival (LRFS) was analyzed with Kaplan-Meier. Toxicity according to Common Terminology Criteria for Adverse Events v5. Variables affecting toxicities were analyzed with chi-squared and Mann-Whitney U tests.</p><p><strong>Results: </strong>Patients received a median CIRTb dose of 15 Gy RBE, with 29 (41%) receiving Ph and 42 (59%) receiving PT. With a median follow-up of 17.23 months, 2-year LRFS achieved 87.8% (95% CI: 79.6-96.8). Female (p = 0.045) reported better 2-year LRFS rates: 95.2% (95% CI: 86.6-100) versus 81.8% (95% CI: 69.5-96.2). Acute and late G2+ toxicity were, respectively, 80% and 60%. Ph (p = 0.004) and smaller LR-CTV (p = 0.004) reduced acute and late toxicities. No G4 late toxicity was reported.</p><p><strong>Conclusions: </strong>CIRT combined with Ph or PT seems a valuable option for locally advanced SGCs and SNCs. Prospective studies are needed to select the best treatment combination.</p>","PeriodicalId":19615,"journal":{"name":"Oral diseases","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COMBINATORIC: Carbon Ion Boost With Photons or Protons in Salivary Gland and Sinonasal Cancers.\",\"authors\":\"Anna Maria Camarda, Giulia Fontana, Barbara Vischioni, Amelia Barcellini, Maria Bonora, Jessica Franzetti, Nadia Facchinetti, Federica Serra, Carmine Tinelli, Rossana Ingargiola, Sara Ronchi, Viviana Vitolo, Pierluigi Bonomo, Sara Colombo, Daniela Alterio, Nicola Alessandro Iacovelli, Marzia Franceschini, Giovanni Ivaldi, Marco Trovò, Elisa D'Angelo, Ester Orlandi\",\"doi\":\"10.1111/odi.70086\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To evaluate the outcomes of combining carbon ion radiotherapy boost (CIRTb) with photons (Ph) or protons (PT) for locally advanced salivary gland and sinonasal cancers (SGCs and SNCs).</p><p><strong>Materials and methods: </strong>Sixty-nine patients with SGCs and SNCs received CIRTb to high-risk CTV and Ph or PT to low-risk CTV (LR-CTV) from October 2014 to September 2022. Two-year local relapse-free survival (LRFS) was analyzed with Kaplan-Meier. Toxicity according to Common Terminology Criteria for Adverse Events v5. Variables affecting toxicities were analyzed with chi-squared and Mann-Whitney U tests.</p><p><strong>Results: </strong>Patients received a median CIRTb dose of 15 Gy RBE, with 29 (41%) receiving Ph and 42 (59%) receiving PT. With a median follow-up of 17.23 months, 2-year LRFS achieved 87.8% (95% CI: 79.6-96.8). Female (p = 0.045) reported better 2-year LRFS rates: 95.2% (95% CI: 86.6-100) versus 81.8% (95% CI: 69.5-96.2). Acute and late G2+ toxicity were, respectively, 80% and 60%. Ph (p = 0.004) and smaller LR-CTV (p = 0.004) reduced acute and late toxicities. No G4 late toxicity was reported.</p><p><strong>Conclusions: </strong>CIRT combined with Ph or PT seems a valuable option for locally advanced SGCs and SNCs. Prospective studies are needed to select the best treatment combination.</p>\",\"PeriodicalId\":19615,\"journal\":{\"name\":\"Oral diseases\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-09-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/odi.70086\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DENTISTRY, ORAL SURGERY & MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/odi.70086","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
COMBINATORIC: Carbon Ion Boost With Photons or Protons in Salivary Gland and Sinonasal Cancers.
Aim: To evaluate the outcomes of combining carbon ion radiotherapy boost (CIRTb) with photons (Ph) or protons (PT) for locally advanced salivary gland and sinonasal cancers (SGCs and SNCs).
Materials and methods: Sixty-nine patients with SGCs and SNCs received CIRTb to high-risk CTV and Ph or PT to low-risk CTV (LR-CTV) from October 2014 to September 2022. Two-year local relapse-free survival (LRFS) was analyzed with Kaplan-Meier. Toxicity according to Common Terminology Criteria for Adverse Events v5. Variables affecting toxicities were analyzed with chi-squared and Mann-Whitney U tests.
Results: Patients received a median CIRTb dose of 15 Gy RBE, with 29 (41%) receiving Ph and 42 (59%) receiving PT. With a median follow-up of 17.23 months, 2-year LRFS achieved 87.8% (95% CI: 79.6-96.8). Female (p = 0.045) reported better 2-year LRFS rates: 95.2% (95% CI: 86.6-100) versus 81.8% (95% CI: 69.5-96.2). Acute and late G2+ toxicity were, respectively, 80% and 60%. Ph (p = 0.004) and smaller LR-CTV (p = 0.004) reduced acute and late toxicities. No G4 late toxicity was reported.
Conclusions: CIRT combined with Ph or PT seems a valuable option for locally advanced SGCs and SNCs. Prospective studies are needed to select the best treatment combination.
期刊介绍:
Oral Diseases is a multidisciplinary and international journal with a focus on head and neck disorders, edited by leaders in the field, Professor Giovanni Lodi (Editor-in-Chief, Milan, Italy), Professor Stefano Petti (Deputy Editor, Rome, Italy) and Associate Professor Gulshan Sunavala-Dossabhoy (Deputy Editor, Shreveport, LA, USA). The journal is pre-eminent in oral medicine. Oral Diseases specifically strives to link often-isolated areas of dentistry and medicine through broad-based scholarship that includes well-designed and controlled clinical research, analytical epidemiology, and the translation of basic science in pre-clinical studies. The journal typically publishes articles relevant to many related medical specialties including especially dermatology, gastroenterology, hematology, immunology, infectious diseases, neuropsychiatry, oncology and otolaryngology. The essential requirement is that all submitted research is hypothesis-driven, with significant positive and negative results both welcomed. Equal publication emphasis is placed on etiology, pathogenesis, diagnosis, prevention and treatment.